From May 11to 15, 2026, the 29th Annual Meetingof the American Societyof Gene + Cell Therapy (ASGCT) was successfully held at the Thomas Menino Conference & Exhibition Center in Boston, USA. This premier industry event brought together global regulatory agencies, leading clinical Principal Investigators (PIs), industry leaders, and investors, collaboratively charting the future blueprintof the Cell and Gene Therapy (CGT) sector with a forward-looking perspective.
As a recognized “bellwether” for the industry, this ASGCT annual meeting gathered top-tier scientists and clinical researchersfrom around the world. The conference focused on core topics such as gene therapy vector design, innovations in gene editing technology, and the clinical translationof cell therapy. Through in-depth intellectual exchange and academic interaction, it explored new opportunities and challenges for industry development in a comprehensive manner.
Conference Scene
At the ASGCT convention, which gathered elite experts from the global biopharmaceutical industry, MingCeler Biotech, a deep cultivator in the fieldof “rapid, personalized genetically modified mouse models,” made a stunning appearance with its core technology—the TurboMice™ tetraploid complementation technology.
Our Chairman, Prof. Guangming Wu, and the Vice Directorof International Business Marketing attended the exhibition.
During the exhibition, the MingCeler Biotech booth attracted a continuous flowof visitors. Addressing the long-standing bottleneck plaguing the biopharmaceutical innovation chain—”prolonged preparation cycles and low efficiency for complex animal models”—the advantageof TurboMice™ technology in “rapid and efficient model construction” sparked widespread interest.
The core advantageof TurboMice™ technology lies in bypassing the time-consuming breeding and
screening steps inherent in traditional methods, significantly shortening the R&D cycle:
Ultra-Short Cycle: Homozygous mice can be obtained in as little as 2 months.
High Efficiency & Precision: Supports efficient editing at nearly any target gene locus.
Precision in Complex Models: For sophisticated genetic models like humanization or multi-target edits, homozygous mice can be delivered within 5 months, supporting rapid optimization and iteration.
TurboMice™ technology provides robust animal model support for new drug development, vaccine evaluation, precision medicine, and research responses to public health emergencies.
Prof. Guangming Wu, Chairmanof our company, and our Vice Directorof International Business Marketing actively introduced products and technologies to clients, engaging in deep business negotiations and technical exchanges with experts, scholars, and corporate representatives from across the globe. The team not only provided detailed answers to various client inquiries regarding model construction but also offered customized solutions tailored to the specific needs of different R&D stages. The on-site interaction was enthusiastic and harmonious.
This ASGCT tour was not only a global showcaseof MingCeler Biotech’s technical strength but also a crucial opportunityto deepen the global biopharmaceutical collaboration network. We are well aware that every exchange serves as a starting point for future cooperation. MingCeler Biotech looks forwardto converting the industry insights and networking resources gained at this conference into strong momentum for advancing the CGT field. Let us move forward hand-in-handto the next summit.
The excitement continues, and the journey does not end. MingCeler Biotech will remain committedto innovating the next generationof animal model preparation technology—TurboMice™ tetraploid complementation—to provide superior mouse models and customization services, empowering the rapid developmentof the biopharmaceutical industry with innovative technology!
